SIGLEC1 and hepatocellular carcinoma: In our recent study (Wu, et al., 2020), we screened nine myeloid markers in both intra-tumoral and peri-tumoral tissues of HCC and then built a myeloid signature (named MRS) based on the IHC features of CD11b and CD169 in the intra-tumoral region.